Literature DB >> 10353947

Thalidomide responsiveness in an infant with Behçet's syndrome.

L P Shek1, Y S Lee, B W Lee, T J Lehman.   

Abstract

BACKGROUND: Behçet's syndrome is a chronic relapsing vasculitis characterized by aphthous stomatitis, genital ulcerations, and uveitis. The disease is a multisystem illness, which may involve the skin, joints, gastrointestinal tract, blood vessels, central nervous system, and other organs. CASE STUDY: We report a case of an infant with features of Behçet's syndrome who did not respond to conventional immunosuppression with high-dose corticosteroids and cytotoxic agents. Thalidomide, a potent immune response-modifying drug, was used with marked improvement and resolution of symptoms.
CONCLUSION: This finding supports a trial of thalidomide treatment in patients with Behçet's syndrome who are unresponsive to other forms of immunosuppressive therapy or develop undesirable side effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353947     DOI: 10.1542/peds.103.6.1295

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  4 in total

Review 1.  Thalidomide in gastrointestinal disorders.

Authors:  A Bousvaros; B Mueller
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Thalidomide: an emerging drug in oral mucosal lesions.

Authors:  K Mubeen; M Ahmed Siddiq; V R Jigna
Journal:  Clin J Gastroenterol       Date:  2009-06-02

Review 3.  Updated treatment strategies for intestinal Behçet's disease.

Authors:  Yong Eun Park; Jae Hee Cheon
Journal:  Korean J Intern Med       Date:  2017-12-08       Impact factor: 2.884

4.  Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.

Authors:  Yue Li; Zelong Han; Xianfei Wang; Zhihui Mo; Wei Zhang; Aimin Li; Side Liu
Journal:  BMC Gastroenterol       Date:  2013-12-09       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.